Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial
Elizabeth O’Donnell, Clifton C. Mo, Andrew J. Yee, Omar Nadeem, Jacob P. Laubach, Jacalyn Rosenblatt, Nikhil C. Munshi, Shonali Midha, Diana Cirstea, Pavlina Chrysafi, Nora Horick, Paul G. Richardson, Noopur Raje
Topics & Concepts
MedicineLenalidomideCarfilzomibMultiple myelomaDexamethasoneInternal medicineOncologyTransplantationMultiple Myeloma Research and TreatmentsImmunotherapy and Immune ResponsesCAR-T cell therapy research